Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
Abstract
:1. Introduction
2. Results
2.1. RNA Sequencing Analyses of 16 GC Patients with NTRK1-3 Overexpression
2.2. Effects of NTRK Inhibitors on GC Cells
2.3. Effects of Entrectinib on Cell Apoptosis in GC Cells Harboring NTRK1/2/3, VEGFR2, TGFBR1, or CD274 Gene Amplification
2.4. Effects of Entrectinib on Gene and Protein Expression Levels in GC Cells
2.5. Effects of Entrectinib on Cell Migration in GC Cells
3. Discussion
4. Materials and Methods
4.1. Cell Culture and Reagents
4.2. Growth Inhibition Assays
4.3. Apoptosis Analysis
4.4. Quantitative Real-Time PCR (qPCR) Analysis
4.5. Immunoblot Analysis
4.6. Cell Migration Analysis
4.7. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Korivi, B.R.; Faria, S.; Aly, A.; Sun, J.; Patnana, M.; Jensen, C.T.; Wagner-Bartak, N.; Bhosale, P.R. Intestinal and diffuse gastric cancer: A retrospective study comparing primary sites. Clin. Imaging 2019, 56, 33–40. [Google Scholar] [CrossRef]
- Rubin, J.B.; Segal, R.A. Growth, survival and migration: The Trk to cancer. Cancer Treat. Res. 2003, 115, 1–18. [Google Scholar]
- Lee, S.J.; Kim, N.K.D.; Lee, S.-H.; Kim, S.T.; Park, S.H.; Park, J.O.; Park, Y.S.; Lim, H.Y.; Kang, W.K.; Park, W.Y.; et al. NTRK gene amplification in patients with metastatic cancer. Precis Future Med. 2017, 1, 129–137. [Google Scholar] [CrossRef] [Green Version]
- Green, J.; Nusse, R.; van Amerongen, R. The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. Cold Spring Harb. Perspect. Biol. 2014, 6, a009175. [Google Scholar] [CrossRef]
- Dailey, L.; Ambrosetti, D.; Mansukhani, A.; Basilico, C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005, 16, 233–247. [Google Scholar] [CrossRef]
- Valenta, T.; Hausmann, G.; Basler, K. The many faces and functions of beta-catenin. EMBO J. 2012, 31, 2714–2736. [Google Scholar] [CrossRef] [Green Version]
- Perry, J.M.; He, X.C.; Sugimura, R.; Grindley, J.C.; Haug, J.S.; Ding, S.; Li, L. Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev. 2011, 25, 1928–1942. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rathore, K.; Choudhary, S.; Odoi, A.; Wang, H.C. Green tea catechin intervention of reactive oxygen species-mediated ERK pathway activation and chronically induced breast cell carcinogenesis. Carcinogenesis 2012, 33, 174–183. [Google Scholar] [CrossRef] [Green Version]
- Lin, S.Y.; Xia, W.; Wang, J.C.; Kwong, K.Y.; Spohn, B.; Wen, Y.; Pestell, R.G.; Hung, M.C. Beta-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 2000, 97, 4262–4266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, W.; Zhang, X.; Wu, F.; Zhou, Y.; Bao, Z.; Li, H.; Zheng, P.; Zhao, S. Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell Death Dis. 2019, 10, 918. [Google Scholar] [CrossRef] [Green Version]
- Smith, B.N.; Bhowmick, N.A. Role of EMT in Metastasis and Therapy Resistance. J. Clin. Med. 2016, 5, 17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vos, M.C.; Hollemans, E.; Ezendam, N.; Feijen, H.; Boll, D.; Pijlman, B.; van der Putten, H.; Klinkhamer, P.; van Kuppevelt, T.H.; van der Wurff, A.A.; et al. MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer. J. Ovarian Res. 2016, 9, 53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cho, S.H.; Park, Y.S.; Kim, H.J.; Kim, C.H.; Lim, S.W.; Huh, J.W.; Lee, J.H.; Kim, H.R. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int. J. Oncol. 2012, 41, 211–218. [Google Scholar] [PubMed] [Green Version]
- Elzarkaa, A.A.; Sabaa, B.E.; Abdelkhalik, D.; Mansour, H.; Melis, M.; Shaalan, W.; Farouk, M.; Malik, E.; Soliman, A.A. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: A prospective study. J. Cancer Res. Clin. Oncol. 2016, 142, 949–958. [Google Scholar] [CrossRef]
- Sohn, S.H.; Sul, H.J.; Choi, Y.; Lee, S.; Kim, B.J.; Kim, H.S.; Koh, Y.; Zang, D.Y. An integrated mRNA–microRNA regulatory network identified INHBA and has-miR-135a-5p as predictors of gastric cancer recurrence. Mol. Cell. Toxicol. 2021, 17, 213–220. [Google Scholar] [CrossRef]
- Okamura, R.; Boichard, A.; Kato, S.; Sicklick, J.K.; Bazhenova, L.; Kurzrock, R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics. JCO Precis Oncol. 2018, 2, 1–20. [Google Scholar] [CrossRef]
- Wang, Q.; Liu, F.; Liu, L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine 2017, 96, e6369. [Google Scholar] [CrossRef]
- Bhola, N.E.; Balko, J.M.; Dugger, T.C.; Kuba, M.G.; Sanchez, V.; Sanders, M.; Stanford, J.; Cook, R.S.; Arteaga, C.L. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Investig. 2013, 123, 1348–1358. [Google Scholar] [CrossRef]
- Massague, J. TGFbeta in Cancer. Cell 2008, 134, 215–230. [Google Scholar] [CrossRef] [Green Version]
- Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E., III; Koeppen, H.; Astarita, J.L.; Cubas, R.; et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018, 554, 544–548. [Google Scholar] [CrossRef]
- Tauriello, D.V.F.; Palomo-Ponce, S.; Stork, D.; Berenguer-Llergo, A.; Badia-Ramentol, J.; Iglesias, M.; Sevillano, M.; Ibiza, S.; Canellas, A.; Hernando-Momblona, X.; et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 2018, 554, 538–543. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, L.; Yang, Q.C.; Li, Y.C.; Yang, L.L.; Liu, J.F.; Li, H.; Xiao, Y.; Bu, L.L.; Zhang, W.F.; Sun, Z.J. Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Cancer Immunol. Res. 2020, 8, 179–191. [Google Scholar] [CrossRef]
- Burr, M.L.; Sparbier, C.E.; Chan, Y.C.; Williamson, J.C.; Woods, K.; Beavis, P.A.; Lam, E.Y.N.; Henderson, M.A.; Bell, C.C.; Stolzenburg, S.; et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 2017, 549, 101–105. [Google Scholar] [CrossRef] [Green Version]
- Claudia, D.A.; Anil, K.R. No one-way street: Cross-talk between E-cadherin and receptor tyrosine kinase (RTK) signaling—A mechanism to regulate RTK activity. Cancer Biol. Ther. 2005, 4, 35–38. [Google Scholar]
- Krejci, P.; Aklian, A.; Kaucka, M.; Sevcikova, E.; Prochazkova, J.; Masek, J.K.; Mikolka, P.; Pospisilova, T.; Spoustova, T.; Weis, M.; et al. Receptor tyrosine kinases activate canonical WNT/beta-catenin signaling via MAP kinase/LRP6 pathway and direct beta-catenin phosphorylation. PLoS ONE 2012, 7, e35826. [Google Scholar] [CrossRef]
- Amatu, A.; Sartore-Bianchi, A.; Siena, S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016, 1, e000023. [Google Scholar] [CrossRef] [Green Version]
- Nakagawara, A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett. 2001, 169, 107–114. [Google Scholar] [CrossRef]
- Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442–454. [Google Scholar] [CrossRef]
- Cai, J.; Guan, H.; Fang, L.; Yang, Y.; Zhu, X.; Yuan, J.; Wu, J.; Li, M. MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J. Clin. Investig. 2013, 123, 566–579. [Google Scholar]
- Gottardi, C.J.; Wong, E.; Gumbiner, B.M. E-cadherin suppresses cellular transformation by inhibiting b-catenin signaling in an adhesion-independent manner. J. Cell Biol. 2001, 153, 1049–1060. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yasui, W.; Oue, N.; Aung, P.P.; Matsumura, S.; Shutoh, M.; Nakayama, H. Molecular-pathological prognostic factors of gastric cancer: A review. Gastric Cancer 2005, 8, 86–94. [Google Scholar] [CrossRef] [PubMed]
- Shook, D.; Keller, R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech. Dev. 2003, 120, 1351–1383. [Google Scholar] [CrossRef] [PubMed]
- Murai, T.; Miyazaki, Y.; Nishinakamura, H.; Sugahara, K.N.; Miyauchi, T.; Sako, Y.; Yanagida, T.; Miyasaka, M. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J. Biol. Chem. 2004, 279, 4541–4550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, X.; Wang, Y.; Xia, H.; Wang, Q.; Jiang, X.; Lin, Z.; Ma, Y.; Yang, Y.; Hu, M. Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. Mol. Biol. Rep. 2012, 39, 6707–6714. [Google Scholar] [CrossRef]
- Kim, S.A.; Inamura, K.; Yamauchi, M.; Nishihara, R.; Mima, K.; Sukawa, Y.; Li, T.; Yasunari, M.; Morikawa, T.; Fitzgerald, K.C.; et al. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br. J. Cancer 2016, 114, 199–206. [Google Scholar] [CrossRef]
- Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704–715. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miyazaki, H.; Takahashi, R.U.; Prieto-Vila, M.; Kawamura, Y.; Kondo, S.; Shirota, T.; Ochiya, T. CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells. Oncotarget 2018, 9, 10029–10041. [Google Scholar] [CrossRef] [Green Version]
- Ayob, A.Z.; Ramasamy, T.S. Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 2018, 25, 20. [Google Scholar] [CrossRef]
- Morgan, R.G.; Mortensson, E.; Williams, A.C. Targeting LGR5 in Colorectal Cancer: Therapeutic gold or too plastic? Br. J. Cancer 2018, 118, 1410–1418. [Google Scholar] [CrossRef]
- Wang, Y.K.; Zhu, Y.L.; Qiu, F.M.; Zhang, T.; Chen, Z.G.; Zheng, S.; Huang, J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010, 31, 1376–1380. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.F.; Chen, M.; Zhu, Y.S.; Dai, X.P.; Dang, F.B.; Ren, J.M.; Ren, S.C.; Shulga, Y.V.; Beca, F.; Gan, W.J.; et al. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Dev. Cell 2019, 48, 329–344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
# | NTRK Expression | Sex | Age | Stage | Lauren | Reccur |
---|---|---|---|---|---|---|
1 | NTRK2 | M | 78 | IIIA | diffuse | N |
2 | NTRK1 | F | 76 | IIB | mixed | N |
3 | NTRK3 | M | 53 | IIIB | mixed | N |
4 | NTRK2 | F | 79 | IIA | mixed | N |
5 | NTRKs 1–3 | F | 82 | IIIB | diffuse | Y |
6 | NTRK1 | F | 76 | IIIB | mixed | N |
7 | NTRKs 1–3 | F | 45 | IIIC | diffuse | Y |
8 | NTRK3 | M | 80 | IIIB | diffuse | N |
9 | NTRKs 2, 3 | M | 68 | IIIA | diffuse | Y |
10 | NTRK1 | M | 74 | IIB | diffuse | N |
11 | NTRK2 | M | 64 | IV | intestinal | N |
12 | NTRK1 | M | 57 | IIIA | intestinal | N |
13 | NTRKs 2, 3 | F | 74 | IIIC | mixed | N |
14 | NTRKs 1–3 | M | 44 | IIIC | diffuse | N |
15 | NTRK1 | M | 54 | IIIC | diffuse | Y |
16 | NTRKs 1, 2 | F | 59 | IIA | diffuse | N |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sohn, S.-H.; Sul, H.J.; Kim, B.J.; Kim, H.S.; Zang, D.Y. Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression. Int. J. Mol. Sci. 2022, 23, 395. https://doi.org/10.3390/ijms23010395
Sohn S-H, Sul HJ, Kim BJ, Kim HS, Zang DY. Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression. International Journal of Molecular Sciences. 2022; 23(1):395. https://doi.org/10.3390/ijms23010395
Chicago/Turabian StyleSohn, Sung-Hwa, Hee Jung Sul, Bum Jun Kim, Hyeong Su Kim, and Dae Young Zang. 2022. "Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression" International Journal of Molecular Sciences 23, no. 1: 395. https://doi.org/10.3390/ijms23010395